Therapeutic Cancer Vaccination with Immunopeptidomics-Discovered Antigens Confers Protective Antitumor Efficacy.
breast cancer
cancer vaccine
endogenous retrovirus
immunopeptidome
immunotherapy
ligandome
mass spectrometry
oncolytic vaccine
tumor antigen
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
07 Jul 2021
07 Jul 2021
Historique:
received:
03
06
2021
revised:
01
07
2021
accepted:
02
07
2021
entrez:
24
7
2021
pubmed:
25
7
2021
medline:
25
7
2021
Statut:
epublish
Résumé
Knowledge of clinically targetable tumor antigens is becoming vital for broader design and utility of therapeutic cancer vaccines. This information is obtained reliably by directly interrogating the MHC-I presented peptide ligands, the immunopeptidome, with state-of-the-art mass spectrometry. Our manuscript describes direct identification of novel tumor antigens for an aggressive triple-negative breast cancer model. Immunopeptidome profiling revealed 2481 unique antigens, among them a novel ERV antigen originating from an endogenous retrovirus element. The clinical benefit and tumor control potential of the identified tumor antigens and ERV antigen were studied in a preclinical model using two vaccine platforms and therapeutic settings. Prominent control of established tumors was achieved using an oncolytic adenovirus platform designed for flexible and specific tumor targeting, namely PeptiCRAd. Our study presents a pipeline integrating immunopeptidome analysis-driven antigen discovery with a therapeutic cancer vaccine platform for improved personalized oncolytic immunotherapy.
Identifiants
pubmed: 34298622
pii: cancers13143408
doi: 10.3390/cancers13143408
pmc: PMC8306067
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : H2020 European Research Council
ID : 681219
Organisme : Jane ja Aatos Erkon Säätiö
ID : 4705796
Organisme : HiLIFE Fellow
ID : 797011004
Organisme : Cancer Finnish Foundation
ID : 4706116
Organisme : Magnus Ehrnroothin Säätiö
ID : 4706235
Organisme : Vetenskapsrådet
ID : 2015-04622
Organisme : Stiftelsen för Strategisk Forskning
Organisme : Cancerfonden
Organisme : Barncancerfonden
Organisme : Cancer Research Funds of Radiumhemmet
Références
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Nat Commun. 2014 Oct 31;5:5277
pubmed: 25358478
Blood. 2009 Aug 20;114(8):1537-44
pubmed: 19423728
Nat Commun. 2020 Nov 9;11(1):5660
pubmed: 33168830
J Clin Invest. 2011 Jun;121(6):2350-60
pubmed: 21555851
J Clin Invest. 2014 May;124(5):2246-59
pubmed: 24667641
Curr Opin Immunol. 2013 Apr;25(2):277-83
pubmed: 23619309
Cancer Immunol Res. 2020 Apr;8(4):544-555
pubmed: 32047025
Sci Data. 2018 Aug 07;5:180157
pubmed: 30084848
Cell Rep. 2018 Apr 10;23(2):512-521
pubmed: 29642008
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Breast Cancer Res. 2012 Mar 15;14(2):R48
pubmed: 22420471
Nucleic Acids Res. 2017 Jul 3;45(W1):W458-W463
pubmed: 28407089
Cancer Discov. 2016 Dec;6(12):1382-1399
pubmed: 27663893
Nat Med. 2016 Apr;22(4):433-8
pubmed: 26901407
Immunogenetics. 2008 Dec;60(12):759-65
pubmed: 18766337
Nat Immunol. 2009 Jan;10(1):29-37
pubmed: 19043418
Nat Med. 2012 Aug;18(8):1254-61
pubmed: 22842478
J Clin Invest. 2018 Nov 1;128(11):4804-4820
pubmed: 30137025
Sci Transl Med. 2018 Jan 3;10(422):
pubmed: 29298865
Breast Cancer Res. 2014 Jul 03;16(4):R70
pubmed: 24992895
Oncoimmunology. 2018 Aug 23;7(11):e1502128
pubmed: 30377566
Nature. 2014 Nov 27;515(7528):572-6
pubmed: 25428506
J Clin Oncol. 2013 Mar 1;31(7):860-7
pubmed: 23341518
Proteomics. 2018 Jun;18(12):e1700465
pubmed: 29786170
Cancer Immunol Res. 2014 Apr;2(4):361-70
pubmed: 24764583
Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14733-8
pubmed: 20679213
Nature. 2019 Jan;565(7738):240-245
pubmed: 30568303
Methods Mol Biol. 2018;1719:209-221
pubmed: 29476514
Nat Commun. 2019 Apr 8;10(1):1600
pubmed: 30962452
Oncoimmunology. 2018 May 7;7(8):e1457596
pubmed: 30221051
Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16899-903
pubmed: 12477932
Cancer Immunol Res. 2021 Jun 8;:
pubmed: 34103348
Oncoimmunology. 2015 Oct 29;5(4):e1105429
pubmed: 27141389
Nucleic Acids Res. 2019 Jan 8;47(D1):D419-D426
pubmed: 30407594
Curr Opin Immunol. 2015 Jun;34:1-8
pubmed: 25466393
Mol Ther Oncolytics. 2021 Feb 10;20:459-469
pubmed: 33718594
J Natl Cancer Inst. 2021 Feb 01;:
pubmed: 33523233
Cell. 2015 Aug 27;162(5):974-86
pubmed: 26317466
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166